Tuesday 15th of March 2022 05:29:44 AM
AbbVie working with Scripps Research to develop COVID-19 antiviral treatments
I going to make a greatest artwork as I can, by my head, my hand and by my mind./iStock via Getty Images
- AbbVie (NYSE:ABBV) will work with Scripps Research on the discovery of new antiviral treatments for COVID-19.
- Scripps has been working on SARS-CoV-2 research through its drug development and discovery division, Calibr.
- The companies say that the research will address gaps in patient needs for COVID treatments.
- Read why Seeking Alpha contributor Cappuccino Finance argues that AbbVie (ABBV) is a hold.